ABBV实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 23:26):

Stats
今日成交量	1.63M
平均成交量	5.73M
市值	283.40B
EPS	$2.79 ( 2024-04-26 )
下一个收益日期	( $2.94 ) 2024-07-25
Last Dividend	$1.550 ( 2024-04-12 )
Next Dividend	$0 ( N/A )
P/E	47.49
ATR14	$0.154 (0.10%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-31	Quaggin Susan E	Buy	82	Stock Equivalent Units
2024-03-31	Alpern Robert J	Buy	41	Stock Equivalent Units
2024-03-31	Rapp Edward J	Buy	212	Stock Equivalent Units
2024-03-20	Donoghoe Nicholas	Sell	21 082	Common Stock, $0.01 par value
2024-03-18	Stewart Jeffrey Ryan	Buy	26 110	Common Stock, $0.01 par value

INSIDER POWER
2.46
Last 100 transactions
Buy: 975 676 \| Sell: 912 577

音量相关性

長: -0.39 (neutral)

短: 0.09 (neutral)

Signal:(61.394) Neutral

Abbvie Inc 相关性

10 最正相关
YSAC	0.891
MOS	0.887
TDI	0.882
NANR	0.865
BML-PJ	0.864
CHH	0.864
VAL	0.86
TMO	0.858
VLTA	0.853
PACK	0.847

10 最负相关
TGH	-0.863
KURE	-0.861
PBC	-0.86
FRGE	-0.859
ALCC	-0.856
SID	-0.854
CE	-0.847
MX	-0.847
FDD	-0.844
WFC-PD	-0.839

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Abbvie Inc 相关性 - 货币/商品

0.64
( weak )

-0.12
( neutral )

-0.65
( moderate negative )

-0.07
( neutral )

0.12
( neutral )

0.22
( neutral )

Abbvie Inc 财务报表

Annual	2023
营收:	$54.32B
毛利润:	$45.54B (83.84 %)
EPS:	$2.73

FY	2023
营收:	$54.32B
毛利润:	$45.54B (83.84 %)
EPS:	$2.73

FY	2022
营收:	$58.05B
毛利润:	$40.64B (70.00 %)
EPS:	$6.65

FY	2021
营收:	$56.20B
毛利润:	$38.75B (68.96 %)
EPS:	$6.53

Financial Reports:

No articles found.

Abbvie Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$1.410 (N/A)	$1.410 (N/A)	$1.480 (N/A)	$1.480 (N/A)	$2.96 (N/A)	$1.480 (N/A)	$1.550 (N/A)	$1.550 (N/A)	$0 (N/A)	$0 (N/A)

Abbvie Inc Dividend Information - Dividend King

Dividend Sustainability Score: 4.65 - low (54.43%) | Divividend Growth Potential Score: 5.68 - Stable (13.60%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.400	2013-01-11
Last Dividend	$1.550	2024-04-12
Next Dividend	$0	N/A
Payout Date	2024-05-15
Next Payout Date	N/A
# dividends	47	--
Total Paid Out	$44.05	--
Avg. Dividend % Per Year	3.70%	--
Score	5	--
Div. Sustainability Score	4.65
Div.Growth Potential Score	5.68
Div. Directional Score	5.16	--

Next Divdend (Est)
(2024-07-01)

$1.580 Estimate 75.00 %

Dividend Stability

1.00 Excellent

Dividend Score

5.00

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2013	$1.600	4.56%
2014	$1.660	3.19%
2015	$2.02	3.07%
2016	$2.28	3.96%
2017	$2.56	4.10%
2018	$3.59	3.65%
2019	$4.28	4.80%
2020	$4.72	5.27%
2021	$5.20	4.93%
2022	$5.64	4.16%
2023	$7.40	4.56%
2024	$3.10	1.94%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
ZTR	Dividend Royal	2024-02-09	Monthly	37	8.35%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.110	1.500	7.79	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.525	1.500	5.28	7.92	[0.1 - 1]
payoutRatioTTM	1.313	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	8.35	1.000	8.02	8.02	[3 - 30]
operatingCashFlowPerShareTTM	10.49	2.00	6.50	10.00	[0 - 30]
freeCashFlowPerShareTTM	10.15	2.00	4.93	9.85	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.720	1.000	1.334	1.334	[0.2 - 0.8]
operatingProfitMarginTTM	0.271	1.000	6.58	6.58	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.65

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	47.93	1.000	5.26	0	[1 - 100]
returnOnEquityTTM	0.525	2.50	6.97	7.92	[0.1 - 1.5]
freeCashFlowPerShareTTM	10.15	2.00	6.62	9.85	[0 - 30]
dividendYielPercentageTTM	4.71	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	10.49	2.00	6.50	10.00	[0 - 30]
payoutRatioTTM	1.313	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	0.261	1.500	-1.595	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.343	1.000	3.93	0	[0.1 - 0.5]
Total Score				5.68

Abbvie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.